2bind Drug Discovery Services
2bind is your one-stop shop for early drug discovery hit identification. We cover all required steps from Assay Development to Screening.
We provide in-house compound and bioactive tool compound librariers and access to fragment libraries.
High-throughput-scale liquid handling completes the early drug-discovery method pipeline.
Click here for a fragment-based drug discovery (FBDD) special!
All the right tools for the job!
We offer the full portfolio of state-of-the art biophysical assay development using MicroScale Thermophoresis and nanoDSF.
Our methods and assays are certified by NanoTemper Technologies.
Assay development covers assay setup, establishment, robustness testing, and transfer to a high-throughput setup.
Biophysical hit screening made easy.
2bind’s partner-network gives you access to computational ligand pre-screening, high-fidelity fragment libraries for fragment-based drug discovery as well as specialized small molecule and bioactive tool compound collections.
Target- or ligand-based pre-screening using novel in silico fingerprint-based algorithms.
> Reduction of library size and complexity.
> Reduction of screening time and costs.
Flexible sourcing of specialized fragment libraries from partners and vendors.
> Tailored selection of library size.
> Specific selection of chemical space.
150.000 small molecule collection and 5050 bioactive tool compound collection from our partner Assay.Works.
> Seamless integration into our processes.
Save on your precious fragments and compounds!
We use ultrasound-based, direct dilution systems (LabCyte Echo platform) for fragment and compound handling.
This enables ultra-fast, contact-less, direct dilution of DMSO stocks with single-digit nL volumes.
No plastic ware used, no sample carryover, no cross-contamination, and absolut minimum compound consumption!
True biophysical high-throughput screening using MicroScale Thermophoresis (MST) and nanoDSF.
Don’t get only a yes-or-no answer for your fragments or compound. Get their true steady-state affinity.
MST and nanoDSF offer the absolute lowest sample consumption for biophysical screening on the market.
Screenings of thousand of compounds can be performed with just a couple of hundred microliters of protein solution.
100 full, 12-point dose-response curves in 10 hours with true steady-state affinity (KD) determination.
Up to 600 single-dose analyses in 10 hours.
> Online quality-controls (target instability, precipitation, and adhesion effects).
> Classification of binders, non-binders, fluorescent-effects, target-aggregation-inducing compounds, etc.
48 target-ligand pairs in parallel with determination of ligand-induced thermal shift of protein denaturation.
480 ligand analyses in 10 hours.
> Online quality-controls (target unfolding, ligand fluorescence).
> Identification of target-aggregation-inducing ligands possible by light scattering.
Hit Validation + Hit Characterization
A number of biophysical paramters is of great intereset in the Hit Validation phase of a drug discovery projects. These include precise steady-state binding affinity to the screening target (KD), as well as the kinetic (kon, koff) and thermodynamic (ΔG, ΔH, ΔS) parameters of hit-target interactions. We cover all these questions with our portfolio of MST, nanoDSF, BLI, and ITC methods.
In hit-to-lead stages, a lower number of drug candidates are typically analyzes with respect to more advanced binding parameters, like stoichiometry, possible competition effects, or their mode-of-action. Moreover, off-target effects have to be carefully investigated, for example by analyzing hit-target interactions in various biological liquids like serum, celly lysate, blood plasma, urine, or the like. Benefit from our higly-variable timelines and project setups to choose the right assay at the right time of the hit-to-lead phase, just as you like.